** Deutsche Bank stays cautious about the European pharmaceutical sector, expecting "the sector malaise" to persist due to political headwinds in the U.S.
** It says that "things have got a little slipperier" for the sector's outlook, though there may also be opportunities
** It adds that while the pan-European index .STOXX is up YTD, the pharma sub-sector .SXDP has fallen, with large pharma down by mid-single digits
** If excluding Novo Nordisk NOVOb.CO, the pharma sector performance would have been slightly better, it says
** Novo Nordisk's shares have fallen 29% YTD
COMPANY | RATING | OLD RATING | PT | OLD PT |
|---|---|---|---|---|
Argenx ARGX.BR | Buy | Hold | EUR 550 | EUR 525 |
Swedish Orphan Biovitrum SOBIV.ST | Hold | Sell | SEK 285 | - |
Curevac CVAC.O 5CV.DE | Hold | - | $5.46 | $3.50 |
Roche ROG.S | Sell | - | CHF 235 | CHF 250 |
Sandoz SDZ.S | Buy | - | CHF 48 | CHF 42 |
Zealand Pharma ZELA.CO | Hold | - | DKK 400 | DKK 485 |
(Reporting by Marta Serafinko in Gdansk)
((Marta.Serafinko@thomsonreuters.com; +48 58 769 66 00;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。